These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19961440)

  • 21. Calcium sensitizing in sepsis: is levosimendan on the right path?
    Morelli A; Ertmer C; Westphal M
    Crit Care Med; 2008 Jun; 36(6):1981-2. PubMed ID: 18520666
    [No Abstract]   [Full Text] [Related]  

  • 22. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
    García-González MJ; Domínguez-Rodríguez A; Ferrer-Hita JJ; Abreu-González P; Muñoz MB
    Eur J Heart Fail; 2006 Nov; 8(7):723-8. PubMed ID: 16492404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
    Avgeropoulou C; Andreadou I; Markantonis-Kyroudis S; Demopoulou M; Missovoulos P; Androulakis A; Kallikazaros I
    Eur J Heart Fail; 2005 Aug; 7(5):882-7. PubMed ID: 15921958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Medical and ventilatory treatment of acute heart failure].
    Hodt A; Steine K; Atar D
    Tidsskr Nor Laegeforen; 2006 Mar; 126(6):749-52. PubMed ID: 16541166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
    Wang L; Cui L; Wei JP; Li GP; Qi GX; Hao YM; Wang WZ; Li HM; Liu J; Jiang DJ; Zhang YD
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock.
    Memiş D; Inal MT; Sut N
    J Crit Care; 2012 Jun; 27(3):318.e1-6. PubMed ID: 21855289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
    Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
    J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
    Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
    Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan and cardiac surgery.
    De Santis V; Vitale D; Tritapepe L
    J Cardiothorac Vasc Anesth; 2010 Feb; 24(1):210. PubMed ID: 19264513
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure.
    Kerbaul F; Gariboldi V; Giorgi R; Mekkaoui C; Guieu R; Fesler P; Gouin F; Brimioulle S; Collart F
    Crit Care Med; 2007 Aug; 35(8):1948-54. PubMed ID: 17568324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocardial efficiency during levosimendan infusion in congestive heart failure.
    Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
    Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A COMPARISON OF TWO APPROACHES FOR INTRAOPERATIVE LEVOSIMENDAN ADMINISTRATION IN CARDIAC SURGICAL PATIENTS WITH SEVERE LEFT VENTRICLE DYSFUNCTION.].
    Pasyuga VV; Belov SI; Yusupova ES; Adzhigaliev RR; Berezhnoy SA; Panov OS; Tarasov DG; Yavorovsky AG
    Anesteziol Reanimatol; 2016 Sep; 61(5):334-338. PubMed ID: 29489098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First Experience With Levosimendan Therapy After Correction of Congenital Heart Disease.
    Giordano R; Cantinotti M; Mannacio VA; Palma G
    J Cardiothorac Vasc Anesth; 2017 Feb; 31(1):e19-e21. PubMed ID: 28277244
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure.
    Mansiroglu AK; Oner E; Erturk M; Karakurt H; Somuncu MU; Birant A; Kalkan AK; Ozturk D; Eksik A
    Acta Cardiol; 2016 Aug; 71(4):411-5. PubMed ID: 27594356
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty.
    Dominguez-Rodriguez A; Samimi-Fard S; Garcia-Gonzalez MJ; Abreu-Gonzalez P
    Int J Cardiol; 2008 Aug; 128(2):214-7. PubMed ID: 17643535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inotropic agents in advanced heart failure: repetita iuvant?
    De Luca L
    Int J Cardiol; 2014 Sep; 176(1):6-7. PubMed ID: 25065330
    [No Abstract]   [Full Text] [Related]  

  • 40. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
    Segreti JA; Marsh KC; Polakowski JS; Fryer RM
    J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.